Innovation in pharmaceuticals, medical devices, diagnostic and digital health technologies has transformed the way we deliver and manage treatments and organize healthcare systems. The challenges in uptake of integrated technologies may hinder patient access to new treatment options, potentially affecting patient outcomes and stifling innovation and commercial success in the European life sciences sector. To better understand the factors that can limit access to transformative technologies, CRA consultants, in collaboration with members of the American Chamber of Commerce to the European Union (AmCham EU) recently analyzed these challenges and opportunities.
To access the full article, click the link below.
Roundtable: Transitioning Medical Affairs to strategically co-lead clinical development and commercialization efforts
In May 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders in Lisbon on best practices in transitioning from a...